Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions rather than financial performance results.
Material Changes
On April 17, 2013, the Administrators of the GlaxoSmithKline Performance Share Plan notified the Company of an increase in notional interests in Ordinary Shares for specific participants. This increase resulted from the notional re-investment of the dividend paid to shareholders on April 11, 2013, at a price of 1565.50 pence per Ordinary Share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Important Facts for Investors
- Transaction Type: Notional re-investment of dividends into Ordinary Shares under the Performance Share Plan.
- Share Price: 1565.50 pence per Ordinary Share.
- Participants: Mr R G Connor, Mr P Thomson, Dr P J T Vallance, Ms E Walmsley, Mr C Weber, and Mrs V A Whyte.
- Settlement Condition: Payouts depend on the vesting percentage of holdings after the three-year measurement period.